Swiss biotechnology company Roche Group (SIX: RO, ROG) (OTCQX: RHHBY) announced on Tuesday that it has secured US Food and Drug Administration (FDA) clearance for its Roche Digital Pathology Dx (VENTANA DP 200) system.
This enables pathologists to use digital slide images for primary diagnosis, improving healthcare efficiency and patient care, particularly in areas with limited access to specialists.
The system is designed to aid the pathologist in reviewing and interpreting digital images of scanned pathology slides to help diagnose patients.
FDA clearance marks a significant step towards routine clinical use of Roche's digital pathology solutions.
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress